Patents by Inventor William D. Thomas

William D. Thomas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10307012
    Abstract: The present disclosure relates to a spray head assembly for a beverage making machine comprising a mounting for connection to a flow of liquid from a reservoir or other water source and a surface for joining to a spray head. A face portion of the spray head has an interior surface with relative rises and depressions or hills and valleys. Orifices are located generally at the peak of a hill with valleys being defined between neighboring hills.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 4, 2019
    Assignee: BUNN-O-MATIC CORPORATION
    Inventors: Burton L. Hart, Randy D. Pope, William H. Thomas
  • Patent number: 10298973
    Abstract: An interactive television program guide system is provided. An interactive television program guide provides users with an opportunity to select programs for recording on a remote media server. Programs may also be recorded on a local media server. The program guide provides users with VCR-like control over programs that are played back from the media servers and over real-time cached copies of the programs. The program guide also provides users with an opportunity to designate gift recipients for whom programs may be recorded.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: May 21, 2019
    Assignee: Rovi Guides, Inc.
    Inventors: Michael D. Ellis, William L. Thomas, Thomas R. Lemmons
  • Publication number: 20190100505
    Abstract: Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: May 15, 2018
    Publication date: April 4, 2019
    Applicant: Pharmacyclics LLC
    Inventors: Wei Chen, Zhaozhong J. Jia, William D. Thomas
  • Patent number: 10221146
    Abstract: The invention provides certain bicyclic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: March 5, 2019
    Assignees: Lycera Corporation, Merck Sharp & Dohme Corp.
    Inventors: Thomas D. Aicher, Chad A. VanHuis, William D. Thomas, John K. MacLean, Brian M. Andresen, Kenneth J. Barr, Corey E. Bienstock, Neville J. Anthony, Matthew Daniels, Kun Liu, Yuan Liu, Catherine M. White, Blair T. Lapointe, Nunzio Sciammetta, Vladimir Simov
  • Publication number: 20190002534
    Abstract: The invention provides human antibodies against rabies and methods of using the same.
    Type: Application
    Filed: August 12, 2016
    Publication date: January 3, 2019
    Applicants: University of Massachusetts, University of Massachusetts
    Inventors: William D. THOMAS, Jr., Yang WANG
  • Publication number: 20180208643
    Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
    Type: Application
    Filed: March 19, 2018
    Publication date: July 26, 2018
    Inventors: Donna M. AMBROSINO, Gregory J. BABCOCK, Teresa BROERING, Robert GRAZIANO, Hector Javier HERNANDEZ, Israel LOWY, Robert MANDELL, Deborah MOLRINE, William D. THOMAS, Jr., Hui-Fen ZHANG
  • Publication number: 20180030005
    Abstract: The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
    Type: Application
    Filed: October 12, 2017
    Publication date: February 1, 2018
    Inventors: Thomas D. Aicher, Chad A. VanHuis, William D. Thomas, John K. MacLean, Brian M. Andresen, Kenneth J. Barr, Corey E. Bienstock, Neville J. Anthony, Matthew Daniels, Kun Liu, Yuan Liu, Catherine M. White, Blair T. Lapointe, Nunzio Sciammetta, Vladimir Simov
  • Publication number: 20180030027
    Abstract: Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are describeded, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: April 12, 2017
    Publication date: February 1, 2018
    Inventors: Wei Chen, Zhaozhong J. Jia, William D. Thomas
  • Patent number: 9809561
    Abstract: The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: November 7, 2017
    Assignees: MERCK SHARP & DOHME CORP., LYCERA CORPORATION
    Inventors: Thomas D. Aicher, Chad A. VanHuis, William D. Thomas, John K. MacLean, Brian M. Andresen, Kenneth J. Barr, Corey E. Bienstock, Neville J. Anthony, Matthew Daniels, Kun Liu, Yuan Liu, Catherine M. White, Blair T. Lapointe, Nunzio Sciammetta, Vladimir Simov
  • Publication number: 20170313722
    Abstract: The invention provides tetrahydronaphthyridine and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydronaphthyridine and related compounds.
    Type: Application
    Filed: May 5, 2017
    Publication date: November 2, 2017
    Inventors: Thomas D. Aicher, Kenneth J. Barr, Blair T. Lapointe, Vladimir Simov, Karin A. Stein, William D. Thomas, Peter L. Toogood, Chad A. VanHuis, Catherine M. White
  • Publication number: 20170226193
    Abstract: The invention provides anti-OspA antibodies and methods of using the same.
    Type: Application
    Filed: August 7, 2015
    Publication date: August 10, 2017
    Inventors: Yang WANG, William D. THOMAS, Jr., Naomi K. BOATRIGHT, Mark S. J. KLEMPNER
  • Patent number: 9657033
    Abstract: The invention provides tetrahydronaphthyridine and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydronaphthyridine and related compounds.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: May 23, 2017
    Assignees: Lycera Corporation, Merck Sharp & Dohme Corp.
    Inventors: Thomas D. Aicher, Kenneth J. Barr, Blair T. Lapointe, Vladimir Simov, Karin A. Stein, William D. Thomas, Peter L. Toogood, Chad A. Van Huis, Catherine M. White
  • Patent number: 9656988
    Abstract: Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: May 23, 2017
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, Zhaozhong J. Jia, William D. Thomas
  • Publication number: 20160355498
    Abstract: Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: June 3, 2016
    Publication date: December 8, 2016
    Inventors: Wei Chen, Zhaozhong J. Jia, William D. Thomas
  • Patent number: 9512111
    Abstract: The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: December 6, 2016
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Peter L. Toogood, Arthur G. Romero, Chad A. Van Huis, Thomas D. Aicher, Carl Kaub, Matthew N. Mattson, William D. Thomas, Karin A. Stein, Erik Krogh-Jespersen, Zhan Wang
  • Publication number: 20160304476
    Abstract: The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
    Type: Application
    Filed: December 19, 2014
    Publication date: October 20, 2016
    Inventors: Thomas D. Aicher, Chad A. VanHuis, William D. Thomas, John K. MacLean, Brian M. Andresen, Kenneth J. Barr, Corey E. Bienstock, Neville J. Anthony, Matthew Daniels, Kun Liu, Yuan Liu, Catherine M. White, Blair T. Lapointe, Nunzio Sciammetta, Vladimir Simov
  • Publication number: 20160287689
    Abstract: The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.
    Type: Application
    Filed: January 4, 2016
    Publication date: October 6, 2016
    Inventors: William D. THOMAS, JR., Paul J. GIANNASCA, Zhenxi ZHANG, Wende LEI, Thomas P. MONATH
  • Patent number: 9409909
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: August 9, 2016
    Assignee: ChemoCentryx, Inc.
    Inventors: Trevor T. Charvat, Cheng Hu, Anita Melikian, Aaron Novack, Andrew M. K. Pennell, Edward J. Sullivan, William D. Thomas, Solomon Ungashe, Penglie Zhang, Jay Powers, Sreenivas Punna
  • Patent number: 9382246
    Abstract: Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: July 5, 2016
    Assignee: Pharmacyclics LLC
    Inventors: Zhaozhong J. Jia, Wei Chen, William D. Thomas
  • Publication number: 20160152694
    Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
    Type: Application
    Filed: October 29, 2015
    Publication date: June 2, 2016
    Inventors: Donna M. AMBROSINO, Gregory J. BABCOCK, Teresa BROERING, Robert GRAZIANO, Hector Javier HERNANDEZ, Israel LOWY, Robert MANDELL, Deborah MOLRINE, William D. THOMAS, JR., Hui-Fen ZHANG